ARIAD , Foundation Medicine Announce Collaboration on AP26113 Study

Foundation Medicine and ARIAD Pharmaceuticals ARIA today announced a genomic profiling collaboration to study AP26113, ARIAD's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer (NSCLC) and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile information for patients enrolled in ARIAD's ongoing Phase 1/2 trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113. “It is important that we have a deep molecular understanding of patients' tumors as they begin treatment with AP26113, especially those patients with complex prior treatment histories,” stated Timothy P. See full press release